Abbott raised its full-year profit guidance on Thursday after posting stronger-than-expected second-quarter earnings, with sales growth across most of its business segments.
Abbott’s adjusted diluted earnings came in at $1.31 a share for the second quarter ended June 30, a step up from the $1.26 it recorded in the same period a year earlier
That topped the Wall Street estimate of $1.28, according to Barron’s. Second-quarter net sales reached $12.59 billion, a 13% increase on a reported basis and 4.8% on a comparable basis. Abbott lifted its full-year 2026 adjusted diluted earnings outlook to a range of $5.45 to $5.60 a share, compared with the $5.38 to $5.58 range it had previously communicated.
The company reaffirmed its full-year comparable sales growth outlook of 6.5% to 7.5%. For the third quarter, Abbott projected adjusted diluted earnings of $1.38 to $1.46 a share. “Our second-quarter results reflect the momentum we are building,” Chairman and Chief Executive Officer Robert B. Ford said in a statement. “We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.” Medical devices, Abbott’s largest segment, posted comparable sales growth of 8.4% in the quarter.